Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Supernus Pharmaceuticals, Inc. - Common Stock
(NQ:
SUPN
)
44.76
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Supernus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
December 03, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 21, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
November 12, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Third Quarter 2025 Financial Results
November 04, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 21, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
September 17, 2025
From
Biogen Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Participate in September Investor Conferences
August 27, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Second Quarter 2025 Financial Results
August 05, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
July 31, 2025
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to...
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
July 28, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
July 22, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 17, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
June 16, 2025
From
Supernus Pharmaceuticals, Inc.; Sage Therapeutics, Inc.
Via
GlobeNewswire
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
May 29, 2025
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
May 28, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
May 28, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
May 20, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces First Quarter 2025 Financial Results
May 06, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
April 23, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in Two Upcoming Investor Conferences
March 04, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
February 27, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
February 25, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
February 18, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 11, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
February 04, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
January 27, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 26, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
November 13, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Third Quarter 2024 Financial Results
November 04, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
